X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/11/15/2781394/0/en/XPHOZAH-tenapanor-Granted-Orphan-Drug-Designation-by-U-S-FDA-for-the-Treatment-of-Pediatric-Hyperphosphatemia.html
https://www.globenewswire.com//news-release/2023/10/23/2764701/0/en/Ardelyx-Shares-Positive-Data-on-Symptom-Response-During-Treatment-With-IBSRELA-tenapanor-for-IBS-C-and-hosts-IBS-C-Product-Theater-at-ACG-2023.html
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-ardelyxs-kidney-disease-related-drug-2023-10-17/
https://www.globenewswire.com//news-release/2023/10/13/2759912/0/en/Ardelyx-to-Present-Data-Updates-for-XPHOZAH-tenapanor-for-Hyperphosphatemia-at-Kidney-Week-2023-November-1-5-in-Philadelphia-PA.html
https://www.globenewswire.com//news-release/2023/10/04/2754523/0/en/Ardelyx-Shares-Preliminary-Data-on-Use-of-IBSRELA-tenapanor-in-Pediatric-IBS-C-Patients-at-NASPGHAN-2023.html
https://www.globenewswire.com//news-release/2023/09/28/2751183/0/en/Ardelyx-Announces-Publication-of-Positive-Results-from-T3MPO-3-Long-Term-Open-Label-Safety-Trial-of-Tenapanor-for-IBS-C-in-the-Journal-of-Neurogastroenterology-and-Motility.html
https://www.globenewswire.com//news-release/2023/09/25/2748372/0/en/Tenapanor-for-Hyperphosphatemia-Approved-in-Japan.html
https://www.globenewswire.com//news-release/2023/09/11/2740770/0/en/Ardelyx-Showcased-Encouraging-Data-on-Treatment-Satisfaction-and-Efficacy-of-IBSRELA-tenapanor-for-IBS-C-at-GHAPP-2023.html
https://www.globenewswire.com/news-release/2023/07/13/2704247/0/en/Ardelyx-Announces-Acceptance-of-New-Drug-Application-for-Tenapanor-for-Hyperphosphatemia-in-China.html
https://www.globenewswire.com/news-release/2023/05/17/2670899/0/en/Ardelyx-Announces-FDA-Acceptance-and-Six-Month-Review-for-Resubmission-of-its-New-Drug-Application-of-XPHOZAH-tenapanor.html
https://www.globenewswire.com/news-release/2023/05/01/2658221/0/en/Ardelyx-Announces-Additional-Data-Supporting-First-In-Class-IBSRELA-tenapanor-for-Adults-with-IBS-C-to-be-Presented-at-the-2023-Digestive-Disease-Week-Conference.html
https://www.globenewswire.com/news-release/2023/04/18/2648943/0/en/Ardelyx-Resubmits-New-Drug-Application-to-U-S-Food-and-Drug-Administration-for-XPHOZAH-tenapanor.html
https://www.prnewswire.com/news-releases/fda-grants-appeal-for-ardelyxs-xphozah-tenapanor-301710866.html
https://www.prnewswire.com/news-releases/ardelyx-provides-update-on-fda-appeal-for-xphozah-tenapanor-for-the-control-of-serum-phosphorus-in-adult-patients-with-chronic-kidney-disease-on-dialysis-301705561.html
https://www.biospace.com/article/ardelyx-s-tenapanor-clears-fda-advisory-committee-hurdle-with-9-4-vote/
https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-stock-trading-halted-today-fda-advisory-committee
https://www.prnewswire.com/news-releases/ardelyx-presents-new-data-analyses-at-kidney-week-2022-further-supporting-the-clinical-relevance-of-xphozah-tenapanor-an-investigational-phosphate-absorption-inhibitor-to-control-serum-phosphorus-in-adult-patients-with-chron-301667715.html
https://www.prnewswire.com/news-releases/ardelyx-collaboration-partner-kyowa-kirin-announces-submission-of-new-drug-application-for-tenapanor-for-hyperphosphatemia-in-japan-301662982.html
https://www.prnewswire.com/news-releases/ardelyx-presents-data-at-ddw-2022-on-ibsrela-tenapanor-a-first-in-class-treatment-for-ibs-c-in-adults-301554355.html
https://www.fiercepharma.com/pharma/ardelyxs-hail-mary-caught-fda-agrees-appeal-convene-advisory-committee-tenapanor
https://endpts.com/crl-appeal-lands-ardelyx-an-fda-adcomm-meeting-for-embattled-ckd-drug/
https://www.prnewswire.com/news-releases/ardelyx-and-kyowa-kirin-amend-license-agreement-for-tenapanor-301522479.html
https://www.hcplive.com/view/fda-issues-letter-ardelyx-submission-tenapanor-chronic-kidney-disease
https://www.prnewswire.com/news-releases/ardelyx-and-kyowa-kirin-highlight-new-data-supporting-the-clinical-safety-and-efficacy-of-first-in-class-phosphate-absorption-inhibitor-tenapanor-at-asns-kidney-week-2020-301158092.html
https://www.prnewswire.com/news-releases/ardelyx-announces-fda-acceptance-for-filing-of-its-new-drug-application-of-tenapanor-for-the-control-of-serum-phosphorus-in-adult-patients-with-ckd-on-dialysis-301130860.html#:~:text=(Nasdaq%3A%20ARDX)%2C%20a,for%20the%20control%20of%20serum
https://www.prnewswire.com/news-releases/ardelyx-announces-submission-of-new-drug-application-to-the-us-fda-for-tenapanor-for-the-control-of-serum-phosphorus-in-adult-patients-with-ckd-on-dialysis-301085645.html
https://www.prnewswire.com/news-releases/ardelyx-announces-positive-second-data-analysis-from-ongoin
https://www.fiercebiotech.com/biotech/ardelyx-s-kidney-disease-drug-hits-goal-phase-3-teeing-up-fda-filing
https://www.biospace.com/article/alfasigma-usa-reintroduces-ibs-c-drug-zelnorm-to-u-s-market/?s=95
https://endpts.com/ardelyx-bags-its-first-fda-ok-for-ibs-setting-up-a-showdown-with-allergan-ironwood/
https://endpts.com/ardelyxs-lead-drug-tenapanor-scores-in-second-hyperphosphatemia-study-shares-leap/
https://www.prnewswire.com/news-releases/ardelyx-announces-peer-reviewed-publication-of-positive-phase-3-results-of-tenapanor-for-the-treatment-of-hyperphosphatemia-in-the-journal-of-the-american-society-of-nephrology-300808726.html
https://www.prnewswire.com/news-releases/ardelyx-announces-fda-acceptance-of-the-filing-of-its-new-drug-application-for-tenapanor-for-the-treatment-of-patients-with-ibs-c-300748969.html
https://endpts.com/constipation-drug-maker-synergy-looks-to-renegotiate-bloated-loan-agreement-shares-tumble/
https://www.prnewswire.com/news-releases/ardelyx-presents-new-preclinical-data-demonstrating-synergy-between-tenapanor-and-sevelamer-when-dosed-in-combination-for-elevated-serum-phosphorus-300738631.html
Market Place
Share 
